BFH772 (VEGFR2 inhibitor): Technical Use and Protocol Guidance

What This Product Solves

BFH772 (CAS 890128-81-1) is a small-molecule VEGFR2 kinase inhibitor designed for research workflows focused on the targeted suppression of VEGFR2-mediated angiogenic signaling. Its selectivity—demonstrated by an IC50 of 3 nM for VEGFR2 and markedly reduced potency against FLK-1, FLT-1, FLT-4, and other kinases—enables precise experimental control in studies of tumor angiogenesis and VEGFR2-dependent signal transduction (product_spec). BFH772's pharmacological profile supports applications where selective inhibition of the VEGFR2 pathway is essential, and off-target kinase effects are undesirable. It is not suitable for protocols requiring water-soluble compounds or broad-spectrum kinase inhibition, as detailed in internal technical articles (related article; related article).

Protocol Parameters

• assay: VEGFR2 kinase inhibition | value_with_unit: IC50 = 3 nM | applicability: Selective inhibition of VEGFR2 in cell-based and biochemical assays | rationale: Enables precise targeting of VEGFR2-mediated angiogenic signaling with minimal off-target kinase inhibition | source_type: product_spec
• assay: Solubility in DMSO | value_with_unit: ≥53.4 mg/mL | applicability: Preparation of concentrated stock solutions for in vitro and in vivo studies | rationale: High solubility in DMSO allows for flexibility in dosing and minimizes precipitation risk during dilution | source_type: product_spec
• assay: Storage temperature | value_with_unit: -20°C (dry powder); avoid long-term solution storage | applicability: Preservation of compound integrity for repeated experimental use | rationale: Minimizes degradation and maintains purity above 96% as confirmed by quality control | source_type: product_spec
• assay: Water solubility | value_with_unit: insoluble | applicability: Not suitable for water-based assay systems or protocols requiring aqueous delivery | rationale: Use alternative vehicles such as DMSO or ethanol for compound formulation | source_type: product_spec

Workflow Setup and QC Checklist

Researchers planning to use BFH772 (VEGFR2 inhibitor) should follow these procedural steps for optimal results:

1. Compound Reconstitution: Dissolve BFH772 in DMSO at concentrations up to 53.4 mg/mL. For in vivo protocols, dilute further in appropriate vehicles compatible with the intended route of administration. Ethanol (up to 15.33 mg/mL) may be used for specific protocols where DMSO is unsuitable (product_spec).
2. Aliquoting and Storage: Prepare aliquots of the DMSO stock and store at -20°C. Avoid repeated freeze-thaw cycles. Do not store working solutions for extended periods; prepare fresh on the day of use to maintain compound integrity.
3. Quality Control Verification: Check the supplied certificate of analysis for purity (>96%) and cross-reference batch numbers. Confirm absence of precipitation or discoloration prior to use.
4. Vehicle Control: Always include vehicle-only controls (e.g., DMSO or ethanol) in experimental design to account for solvent effects.
5. Assay Design: Given the compound’s selectivity, design workflows to specifically probe VEGFR2-dependent pathways. Avoid protocols requiring inhibition of a broad kinase spectrum, as BFH772 demonstrates >40-fold lower potency against kinases like B-RAF, RET, and TIE-2 (product_spec).

Common Failure Modes and Fixes

• Precipitation in aqueous buffers: BFH772 is insoluble in water. Solution: Use only DMSO or ethanol as solvents and ensure compound is fully dissolved before dilution into culture media. Maintain final solvent concentrations within cell-tolerant ranges.
• Loss of potency over time: Storing reconstituted solutions for extended periods or repeated freeze-thaw cycles can degrade compound. Solution: Prepare fresh working solutions daily and store dry powder at -20°C as per product specification.
• Unexpected off-target effects: Although highly selective, off-target activity may occur at high concentrations. Solution: Use concentrations close to the IC50 for VEGFR2 and validate specificity using appropriate negative controls and pathway readouts.
• Vehicle toxicity to cells: High solvent concentrations (DMSO/ethanol) can be cytotoxic. Solution: Optimize dosing to keep solvent below 0.1–0.5% v/v in cell-based assays and always include matched vehicle controls.

Scope and Limitations

BFH772 is highly effective as a VEGFR2 signaling pathway inhibitor in settings where selective, potent inhibition of VEGFR2 is required. It is not suitable for workflows that demand aqueous solubility or inhibition of multiple kinases. Researchers should avoid using BFH772 in protocols where vehicle compatibility is limited or where broad-spectrum anti-angiogenic effects are sought. Its application is best confined to VEGFR2-driven angiogenesis studies, including tumor angiogenesis research, where selectivity and solubility profiles are compatible with workflow design (related article).

Conclusion

BFH772 (VEGFR2 inhibitor) is a rigorously characterized, selective inhibitor for research applications targeting VEGFR2-mediated angiogenesis. Its defined IC50, solubility, and storage parameters enable reproducible and controlled inhibition of VEGFR2 signaling in vitro and in vivo, provided researchers adhere to recommended solubility and handling protocols (APExBIO product_spec). For detailed technical parameters and recommended workflows, consult the supplier’s quality control documentation and internal technical articles referenced above.